These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 25014506)

  • 1. Genetic variance in ABCB1 and CYP3A5 does not contribute toward the development of chronic kidney disease after liver transplantation.
    Tapirdamaz Ö; Hesselink DA; el Bouazzaoui S; Azimpour M; Hansen B; van der Laan LJ; Polak WG; Kwekkeboom J; van Schaik RH; van Gelder T; Metselaar HJ
    Pharmacogenet Genomics; 2014 Sep; 24(9):427-35. PubMed ID: 25014506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part II.
    Staatz CE; Goodman LK; Tett SE
    Clin Pharmacokinet; 2010 Apr; 49(4):207-21. PubMed ID: 20214406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CYP3A5 and ABCB1 polymorphisms in donor and recipient: impact on Tacrolimus dose requirements and clinical outcome after renal transplantation.
    Glowacki F; Lionet A; Buob D; Labalette M; Allorge D; Provôt F; Hazzan M; Noël C; Broly F; Cauffiez C
    Nephrol Dial Transplant; 2011 Sep; 26(9):3046-50. PubMed ID: 21677300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of CYP3A5 genotypes on tacrolimus dose requirement: age and its pharmacological interaction with ABCB1 genetics in the Chinese paediatric liver transplantation.
    Yang TH; Chen YK; Xue F; Han LZ; Shen CH; Zhou T; Luo Y; Zhang JJ; Xia Q
    Int J Clin Pract Suppl; 2015 May; (183):53-62. PubMed ID: 26176181
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship of CYP3A5 genotype and ABCB1 diplotype to tacrolimus disposition in Brazilian kidney transplant patients.
    Cusinato DA; Lacchini R; Romao EA; Moysés-Neto M; Coelho EB
    Br J Clin Pharmacol; 2014 Aug; 78(2):364-72. PubMed ID: 24528196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of CYP3A5 and ABCB1 Gene Polymorphisms on Tacrolimus Blood Concentration in Renal Transplant Recipients.
    Yildirim E; Şahin G; Kaltuş Z; Çolak E
    Clin Lab; 2019 Nov; 65(11):. PubMed ID: 31710427
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenetics of calcineurin inhibitors in Brazilian renal transplant patients.
    Santoro A; Felipe CR; Tedesco-Silva H; Medina-Pestana JO; Struchiner CJ; Ojopi EB; Suarez-Kurtz G
    Pharmacogenomics; 2011 Sep; 12(9):1293-303. PubMed ID: 21806386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of CYP3A5 genetic polymorphism on tacrolimus daily dose requirements and acute rejection in renal graft recipients.
    Quteineh L; Verstuyft C; Furlan V; Durrbach A; Letierce A; Ferlicot S; Taburet AM; Charpentier B; Becquemont L
    Basic Clin Pharmacol Toxicol; 2008 Dec; 103(6):546-52. PubMed ID: 19067682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 1199G>A and 2677G>T/A polymorphisms of ABCB1 independently affect tacrolimus concentration in hepatic tissue after liver transplantation.
    Elens L; Capron A; Kerckhove VV; Lerut J; Mourad M; Lison D; Wallemacq P; Haufroid V
    Pharmacogenet Genomics; 2007 Oct; 17(10):873-83. PubMed ID: 17885626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CYP3A5 and ABCB1 polymorphisms in living donors do not impact clinical outcome after kidney transplantation.
    Yang L; de Winter BC; van Schaik RH; Xie RX; Li Y; Andrews LM; Shuker N; Bahmany S; Koch B; van Gelder T; Hesselink DA
    Pharmacogenomics; 2018 Jul; 19(11):895-903. PubMed ID: 29991328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of donor and recipient CYP3A5 and ABCB1 genetic polymorphisms on tacrolimus dosage requirements and rejection in Caucasian Spanish liver transplant patients.
    Gómez-Bravo MA; Salcedo M; Fondevila C; Suarez F; Castellote J; Rufian S; Pons JA; Alamo JM; Millán O; Brunet M
    J Clin Pharmacol; 2013 Nov; 53(11):1146-54. PubMed ID: 23900887
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CYP3A5 and ABCB1 polymorphisms influence tacrolimus concentrations in peripheral blood mononuclear cells after renal transplantation.
    Capron A; Mourad M; De Meyer M; De Pauw L; Eddour DC; Latinne D; Elens L; Haufroid V; Wallemacq P
    Pharmacogenomics; 2010 May; 11(5):703-14. PubMed ID: 20415563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CYP3A5 and CYP3A4, but not ABCB1 polymorphisms affect tacrolimus dose-adjusted trough concentrations in kidney transplant recipients.
    Kurzawski M; Dąbrowska J; Dziewanowski K; Domański L; Perużyńska M; Droździk M
    Pharmacogenomics; 2014 Feb; 15(2):179-88. PubMed ID: 24444408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients.
    Fukudo M; Yano I; Yoshimura A; Masuda S; Uesugi M; Hosohata K; Katsura T; Ogura Y; Oike F; Takada Y; Uemoto S; Inui K
    Pharmacogenet Genomics; 2008 May; 18(5):413-23. PubMed ID: 18408564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tacrolimus dose requirement in relation to donor and recipient ABCB1 and CYP3A5 gene polymorphisms in Chinese liver transplant patients.
    Wei-lin W; Jing J; Shu-sen Z; Li-hua W; Ting-bo L; Song-feng Y; Sheng Y
    Liver Transpl; 2006 May; 12(5):775-80. PubMed ID: 16628701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The functional implications of common genetic variation in CYP3A5 and ABCB1 in human proximal tubule cells.
    Knops N; van den Heuvel LP; Masereeuw R; Bongaers I; de Loor H; Levtchenko E; Kuypers D
    Mol Pharm; 2015 Mar; 12(3):758-68. PubMed ID: 25590378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Donor and recipient P450 gene polymorphisms influence individual pharmacological effects of tacrolimus in Chinese liver transplantation patients.
    Liu J; Ouyang Y; Chen D; Yao B; Lin D; Li Z; Zang Y; Liu H; Fu X
    Int Immunopharmacol; 2018 Apr; 57():18-24. PubMed ID: 29454235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Personalized tacrolimus dose requirement by CYP3A5 but not ABCB1 or ACE genotyping in both recipient and donor after pediatric liver transplantation.
    Chen YK; Han LZ; Xue F; Shen CH; Lu J; Yang TH; Zhang JJ; Xia Q
    PLoS One; 2014; 9(10):e109464. PubMed ID: 25310192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of pharmacokinetics and pharmacogenetics of once- and twice-daily tacrolimus in the early stage after renal transplantation.
    Niioka T; Satoh S; Kagaya H; Numakura K; Inoue T; Saito M; Narita S; Tsuchiya N; Habuchi T; Miura M
    Transplantation; 2012 Nov; 94(10):1013-9. PubMed ID: 23073468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liver Transplant Patient Carriers of Polymorphism Cyp3a5*1 Donors May Need More Doses of Tacrolimus From the First Month After Transplantation.
    Argudo A; González de Aledo JM; Alía P; Ramírez P; Serrano T; Fabregat J; Castellote J
    Transplant Proc; 2015 Oct; 47(8):2388-92. PubMed ID: 26518936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.